MORE ABOUT HKUST
University News
Academic Departments A-Z
Life@HKUST
Library
Map & Directions
Jobs@HKUST
Faculty Profiles
About HKUST

Search

More About HKUST
Home Why LIFS? Careers Contact Us
HKUST HKUST Division of Life Science
Research
FacultyResearch AreasFacilities
Education
Undergraduate
ProgramsScholarshipsCurriculumAdmissionCoursesResearch ProjectsInternshipsUndergraduate Advising TeamArticulation Pathways
Postgraduate
MPhil/PhD in Life SciencePhD Dual-degree ProgrammeMSc in BiotechnologyAdmissionCoursesSummer Camp
QA at HKUST
News & Events
NewsEvents
Home
August 5, 2020 by LIFS Editor News 0 comments

Mechanism of chemoresistance in brain cancer patients revealed

Gliomas, including glioblastoma (GBM, grade IV) and lower grades (grade II and III) gliomas are the most common and aggressive brain tumors. At present, temozolomide (TMZ) is an oral chemotherapy drug recommended to all GBMs and high-risk lower-grade gliomas. Unfortunately, up to 40-50% of patients are intrinsically resistant to TMZ. Prof. Jiguang Wang and his collaborators from the Beijing Tiantan Hospital and the Spanish National Cancer Research Center elucidated the mechanism of resistance to TMZ in a subset of glioma patients and published their research in Nature Communications. Their work provides the foundation for personalized chemotherapy and potentially leads to methods for overcoming drug resistance in cancer patients.

TMZ can methylate DNA at the O-6 positions of guanine, which is one of the four chemical bases in DNA. The production of methylated guanine at the O-6 position (O6-Methylguanine) can cause DNA double-strand breaks and cell cycle arrest resulting in cell death. However, some cells can repair this type of DNA damage by expressing MGMT (O-6-methylguanine-DNA methyltransferase), therefore reducing the therapeutic effect of TMZ.

Epigenetic silencing of the MGMT gene, by methylating its promoter, can prevent the production of MGMT protein; hence increasing the cell sensitivity to the effect of TMZ. The research team discovered that around 3% of recurrent glioma patients have genomic rearrangements that cause MGMT overexpression regardless of its promoter methylation status. The team used the CRISPR-Cas9 genomic editing tool to replicate some of these genomic rearrangements in different cell and animal models and confirmed that these alterations in the genome, especially the translocation in chromosome 10, drive chemotherapy resistance.

Prof. Wang commented, “For cancer biology, this study advances the understanding of the drug resistance mechanism, and it might shed light on new ideas to overcome this problem. For glioma patients, the finding from this study will provide a biomarker to identify patients who will not benefit from TMZ chemotherapy.”

This research work was accomplished through an international collaboration between Beijing Tiantan Hospital (providing clinical patients), Spanish National Cancer Research Center (performing biological experiments for validation) and HKUST (Wang lab, carrying out computational analysis by identifying and characterizing the key genetic event, i.e. the hypermutation and novel MGMT translocation). In particular, Quanhua Mu is the co-first author (Bioengineering student), Zhaoshi Bao is a contributing author (Postdoctoral fellow at LIFS) and Prof. Wang is the corresponding author.

Journal Reference:

Oldrini B, Vaquero-Siguero N, Mu Q, Kroon P, Zhang Y, Galan-Ganga M, Bao Z, Wang Z, Liu H, Sa JK, Zhao J, Kim H, Rodriguez-Perales S, Nam D, Verhaak RGW, Rabadan R, Jiang T, Wang J, Squatrito M. MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas. Nat Commun. 2020 Aug 11;3883. doi: 10.1038/s41467-020-17717-0.

publication research
1

Related Posts

Pathogenesis of Usher syndrome, a hereditary deafness disease

September 30, 2019
Read More

Hong Kong Life Sciences Scholarship Awards 2022

November 1, 2022
Read More

Best teaching assistant award 2017/18

November 23, 2018
Read More

Prof. Angela Wu awarded ASPIRE League Partnership Seed Fund

September 2, 2020
Read More

A novel molecular mechanism regulating planar cell polarity, shedding light on drug design for cancer treatmentPrevious Post
Prof. Karl Tsim and Prof. Andrew Miller received Health and Medical Research Fund (HMRF) grantNext Post

ADDRESS

Division of Life Science
The Hong Kong University of Science and Technology
Clear Water Bay
Kowloon, Hong Kong

PHONE

Facsimile No. :
(852) 2358 1552

Telephone No. :
(852) 2358-7272 / 7339
  • Home
  • Careers
  • Contact us
  • Faculty
  • Intranet
HKUST
PrivacySitemap
Copyright © The Hong Kong University of Science and Technology.All rights reserved.
Follow HKUST on
FacebookInstagramLinkedinYouTube
PrivacySitemap